Win in Vioxx case is sixth for Merck

Share this article:
A federal jury in New Orleans found in favor of Merck, rejecting a claim that Vioxx caused a man’s 2003 heart attack. The case marked the 11th for Merck involving the withdrawn pain drug. Of these it has won six—including three out of four federal cases—and lost four. (A remaining trial in New Jersey was rescheduled after being overturned.) The company still faces about 24,000 lawsuits and has pledged to address them on an individual basis. The plaintiff in the latest federal case, Charles Laron Mason, took Vioxx for about 10 months before his heart attack but admitted he had not taken it in the days before his heart attack. The jury determined that Merck acted appropriately in the development and marketing of Vioxx and that the drug did not substantially contribute to Mason’s heart attack. Vioxx was withdrawn in 2004 after a study linked it to heart risks. Mason has not decided whether to appeal, his lawyer told the Associated Press. US District Court Judge Eldon Fallon, who is overseeing all of the federal Vioxx litigation, said he wants to press for a settlement after the next federal case, The Wall Street Journal reported.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.